|
PANAMutyper™ R EGFR
|
|
폐암은 암세포가 기관지나 폐포에서 발생하여 혈관이나 림프관을 타고 증식하는 전이성 암으로서, 암세포의 크기와 형태에 따라 비소세포 (non-small cell)암과 소세포 (small cell)암으로 구분된다. 이중 전체 폐암의 약 75%가 비소세포폐암 (NSCLC)으로 분류되며, 나머지 25%가 소세포폐암이다. 폐암은 초기 발견이 어려우며 진행된 상태에서 주로 진단되기 때문에 나쁜 예후를 나타낸다. 표적치료제인 티로신 키나제 저해제 (tyrosine kinase inhibitor; TKI)의 일종인 gefitinib (Iressa; 이레사)나 erlotinib (Tarceva; 타세바)은 EGFR (Epidermal growth factor receptor) 돌연변이 양성인 환자에게 반응성이 매우 높다고 알려져 있다. 폐암환자의 EGFR 유전형의 돌연변이 검출은 치료 전 약물 반응성 예측이 가능하여 효과적인 폐암치료가 가능해질 것으로 기대된다.
|
PANAMutyper™R EGFR |
| Product Name |
|
Cat No. |
|
Size
|
| PANAMutyper™ R EGFR |
|
PNAR-3001 |
|
24 Tests / Kit |
|
|
|
|
|
|
|
EGFR Mutation Details (Genotyping: 47 Mutations) |
| No. |
Reagent |
Exon |
Amino Acid Change |
Nucleotide change |
Cosmic No. |
| 1 |
G719 |
E18 |
G719A |
c.2156G>C |
6239 |
| 2 |
G719S |
c.2155G>A |
6252 |
| 3 |
G719C |
c.2155G>T |
6253 |
| 4 |
E19del A |
19 |
p.E746_A750del |
c.2235_2249 del 15 |
6223 |
| 5 |
p.E746_A750del |
c.2236_2250 del 15 |
6225 |
| 6 |
p.E746_T751>IP |
c.2235_2251>AATTC |
13552 |
| 7 |
p.K745_E749del |
c.2233_2247 del 15 |
26038 |
| 8 |
p.E746_T751>I |
c.2235_2252 AAT (complex) |
13551 |
| 9 |
p.E746_A750del |
c.2235_2248>AATTC |
13550 |
| 10 |
p.L747_S752>Q |
c.2239_2256>CAA |
12403 |
| 11 |
p.S752_I759del |
c.2253_2276 del 24 |
12416 |
| 12 |
p.E746_T751>VA |
c.2237_2253>TTGCT |
12422 |
| 13 |
p.E746_T751>A |
c.2237_2251 del 15 |
12678 |
| 14 |
p.L747_T751del |
c.2239_2253 del 15 |
6254 |
| 15 |
p. L747_T751del |
c.2238_2252 del 15 |
23571 |
| 16 |
p.L747_T751>Q |
c.2238_2252>GCA(complex) |
12419 |
| 17 |
E19del B |
19 |
p.L747_T751del |
c.2240_2254 del 15 |
12369 |
| 18 |
p.L747_T751del |
c.2239_2253 del 15 |
6254 |
| 19 |
p.E746_T751>V |
c.2237_2252>T |
12386 |
| 20 |
p.E746_S752>I |
c.2235_2255>AAT |
12385 |
| 21 |
p.L747_T751del |
c.2238_2252 del 15 |
23571 |
| 22 |
p.E746_T751del |
c.2236_2253 del 18 |
12728 |
| 23 |
p.E746_S752>A |
c.2237_2254 del 18 |
12367 |
| 24 |
p.E746_S752>V |
c.2237_2255>T (complex) |
12384 |
| 25 |
p.E746_S752>D |
c.2238_2255 del 18 |
6220 |
| 26 |
p.L747_A750>P |
c.2238_2248>GC(complex) |
12422 |
| 27 |
p.L747_E749del |
c.2239_2247 del 9 |
6218 |
| 28 |
p.L747_S752del |
c.2239_2256 del 18 |
6255 |
| 29 |
p.L747_ A750>P |
c.2239_2248 TTAAGAGAAG>C |
12382 |
| 30 |
p.L747_P753>Q |
c.2239_2258>CA(complex) |
12387 |
| 31 |
p.L747_T751>S |
c.2240_2251 del 12 |
6210 |
| 32 |
p.L747_P753>S |
c.2240_2257 del 18 |
12370 |
| 33 |
p.L747_T751>P |
c.2239_2251>C(complex) |
12383 |
| 34 |
p.E746_P753>VS |
c.2237_2257>TCT |
18427 |
| 35 |
S768I |
20 |
S768I |
c.2303G>T |
6241 |
| 36 |
T790M |
20 |
T790M |
c.2369C>T |
6240 |
| 37 |
E20ins A |
20 |
p.D770_N771insG |
c.2310_2311 insGGT |
12378 |
| 38 |
p.P772_H773insTTP |
c.2315_2316 insGACAACCCC |
|
| 39 |
p.P772_H773insGNP |
c.2315_2316 insGGGCAACCC |
|
| 40 |
p.V769_N770insASV |
c.2309_2310 AC>CCAGCGTGGAT |
13558 |
| 41 |
E20ins B |
20 |
p.V769_D770insASV |
c.2307_2308 ins GCCAGCGTG |
12376 |
| 42 |
p.H773_V774insH |
c.2319_2320 insCAC |
12377 |
| 43 |
p.H773L |
c.2318 A>T |
13005 |
| 44 |
p.H773_V774insPH |
c.2319_2320 insCCCCAC |
12380 |
| 45 |
p.V774_C775insHV |
c.2321_2322 insCCACGT |
18432 |
| 46 |
p.D770_N771insSVD |
c.2311_2312 ins GCGTGGACA |
13428 |
| 47 |
L858R |
21 |
L858R |
c.2573T>G |
6224 |
| 48 |
L858R |
c.2573_2574 TG>GT |
12429 |
| 49 |
L861Q |
L861Q |
c.2582T>A |
6213 |
|
EGFR Exon21 L858R M & L858R 검출예시(Genotyping &Sensitivity) |
 |
EGFR Exon20 T790M 검출예시(Sensitivity) |
 |
Preparation |
EGFR Exon20 T790M cell line mix |
|
 mutant type: H1975
|
|
wild type: A549
|
|
A549 : L858R M clone ratio variation test ⇒ 100%, 10%, 1%, 0.1%, 0.01%, 0 % of L858R M clone
|
|
A549 : H1975 ratio variation test ⇒ 100%, 10%, 1%, 0.1%, 0.01%, 0 % of H1975
|
EGFR Exon21 L858R M cell line mix |
|
mutant type: L858R M clone
|
|
wild type: A549
|
EGFR Exon21 L858R cell line mix |
|
mutant type:H1975
|
|
wild type: A549
|
|
Features |
|
Ready-to-use kit with result available within 3 hours.
|
|
PNA based mutant enrich genotyping kit- 20 mutations genotyping is possible.
|
|
Compatible Real Time PCR - Bio-Rad CFX96
|
|
Compatible Sample - Plasma/Serum, FFPE, Fresh tissue
|
|
Test Several Biomarkers in One Plate with same PCR conditions - eg. EGFR+KRAS+NRAS in one plate
|
|
Excellent Sensitivity - It can be detected less than 0.1% mutant.
|
|
|
 |
| 1 |
Hitoshi et al., Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation. Cancer Sci. 99(3): 595-600, 2008 |
|
| 2 |
Minakshi ea al., DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation. PLoS ONE. 8(6): e67782, 2013 |
|
| 3 |
Kiyoaki et al., Detection of EGFR Mutations in Archived Cytologic Specimens of Non-Small Cell Lung Cancer Using High-Resolution Melting Analysis. Am J Clin Pathol. 126:608-615, 2006 |
|
| 4 |
Hongdo et al., High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer. 8(142):1-14, 2008 |
|
|
|